Dstock, I agree with you completely that any BP that even dabbles in Oncology is paying attention to NWBO. Essentially I believe most of these BP's have an opinion of what their products will do if combined in treatment with DCVax-L or Direct. Some, like Merck, certainly believe that there are synergies where the approval of the DCVax's will actually enhance their sales. Others will see their products as totally threatened by the DCVax's.
Partnerships to run trials combining DCVax-L with other BP products are almost certain, the BP may pay substantially for the trial. I really don't believe that LP would sell a substantial stock position to any BP at much under $20, but such buy-ins could be part of such agreements at strike prices that probably wouldn't be fully disclosed.
Most biotech's have previously said they didn't want to reveal information they could because it would be of advantage to their competition. From what I've gathered most BP's have sources practically everywhere and often know more about what's happening in a trial than the trial sponsor because the sponsor is restricted from knowing what's happening, while the BP has spies.
An approval in the UK should open the door to many things starting to happen, some of them LP will discuss, others will be happening under the radar until they reach the point they'll be announced. If LP is intending to take on equity partners in the foreseeable future, I believe she'll use that as a reason to once again raise the authorized shares when they hold the next Annual Meeting. If she doesn't bring it up, it's alway possible to have a special meeting to both accept such a partnership and authorize the additional shares if that is desired later.
As I see it, allowing roughly 30 days for an Annual Meeting once it's announced, we'd be looking at late May, and more likely June at the earliest. I really don't know if they'll call it the 2024 Meeting, or the 2023, or perhaps the 2023-2024 Meeting, but I really don't believe we'll have two Annual Meetings within this calendar year. Of course if LP has a reason she wants a second meeting this year, we'd have it.
To me, one of the biggest achievements the company should make this year is a listing on the Nasdaq or NYSE. I don't believe it can happen instantly on reaching the required share price, but a matter of months later as long as the share price is sustained. It's possible that after approval is announced the Nasdaq will want us back and agree to relist us at below the $4 required for a new listing because we were previously listed there before. I say that, but I've gathered that LP really wants us on the NYSE so I really have no idea if she'd go after a Nasdaq listing sooner. The big change that happens once we're on a major exchange is greater Institutional investment. Some Institutions can invest on meeting their minimum price, but many also require being on a major exchange. By the end of this year I believe we'll be on a major exchange and probably at least 25% Institutionally owned. If NWBO is as successful as I believe it will be, it won't be that long before Institutions will have majority ownership and if it's not bought out, at some point they may have 80 to 90% of the company. Individual investors will make the greatest percentage gains, but Institutions will make the greatest dollar gains.
Gary
